GU Cancers 2024 | What are the latest biomarkers for urothelial carcinoma?

Anand Sharma, MD, DPhil, MBBS, MRCP, Mount Vernon Cancer Centre, Northwood, UK, comments on the most recent developments in the field of biomarkers for urothelial cancer. In addition to PD-L1, FGFR and HER2 have been identified as biomarkers and therapies targeting these mutations have additionally been successful in trials. In the case of HER2, multiple agents targeting HER2 indicated for breast cancer may have potential activity in bladder cancer. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.